| __timestamp | BioMarin Pharmaceutical Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 5496000 |
| Thursday, January 1, 2015 | 402271000 | 9786000 |
| Friday, January 1, 2016 | 476593000 | 6792000 |
| Sunday, January 1, 2017 | 554336000 | 7313000 |
| Monday, January 1, 2018 | 604353000 | 8382000 |
| Tuesday, January 1, 2019 | 680924000 | 10803000 |
| Wednesday, January 1, 2020 | 737669000 | 12944000 |
| Friday, January 1, 2021 | 759375000 | 21967000 |
| Saturday, January 1, 2022 | 854009000 | 32810000 |
| Sunday, January 1, 2023 | 937300000 | 46542000 |
| Monday, January 1, 2024 | 1009025000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by approximately 210% from 2014 to 2023, reflecting its aggressive expansion and marketing strategies. In contrast, Xenon Pharmaceuticals, while smaller in scale, has seen a remarkable increase of over 740% in the same period, indicating its growing footprint in the market.
BioMarin's consistent rise in SG&A expenses, peaking at nearly $937 million in 2023, underscores its commitment to maintaining a strong market presence. Meanwhile, Xenon's expenses, reaching around $46 million, highlight its strategic investments in growth. These trends offer a window into the evolving dynamics of the pharmaceutical industry, where strategic financial management is key to sustaining competitive advantage.
Incyte Corporation or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Breaking Down SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Alkermes plc and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.